Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

174 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mesenchymal stem cells expanded in vitro with human serum for the treatment of acute and chronic graft-versus-host disease: results of a phase I/II clinical trial.
Pérez-Simon JA, López-Villar O, Andreu EJ, Rifón J, Muntion S, Diez Campelo M, Sánchez-Guijo FM, Martinez C, Valcarcel D, Cañizo CD. Pérez-Simon JA, et al. Among authors: valcarcel d. Haematologica. 2011 Jul;96(7):1072-6. doi: 10.3324/haematol.2010.038356. Epub 2011 Mar 10. Haematologica. 2011. PMID: 21393326 Free PMC article. Clinical Trial.
Immune Reconstitution Profiling Suggests Antiviral Protection after Transplantation with Omidubicel: A Phase 3 Substudy.
Szabolcs P, Mazor RD, Yackoubov D, Levy S, Stiff P, Rezvani A, Hanna R, Wagner J, Keating A, Lindemans CA, Karras N, McGuirk J, Hamerschlak N, López-Torija I, Sanz G, Valcarcel D, Horwitz ME. Szabolcs P, et al. Among authors: valcarcel d. Transplant Cell Ther. 2023 Aug;29(8):517.e1-517.e12. doi: 10.1016/j.jtct.2023.04.018. Epub 2023 Apr 28. Transplant Cell Ther. 2023. PMID: 37120136 Free article. Clinical Trial.
Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation.
Pérez-Simón JA, Díez-Campelo M, Martino R, Brunet S, Urbano A, Caballero MD, de León A, Valcárcel D, Carreras E, del Cañizo MC, López-Fidalgo J, Sierra J, San Miguel JF. Pérez-Simón JA, et al. Among authors: valcarcel d. Br J Haematol. 2005 Aug;130(3):394-403. doi: 10.1111/j.1365-2141.2005.05614.x. Br J Haematol. 2005. PMID: 16042689 Free article.
Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Piñana JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simón JA, Sierra J. Valcárcel D, et al. J Clin Oncol. 2008 Feb 1;26(4):577-84. doi: 10.1200/JCO.2007.11.1641. Epub 2007 Dec 17. J Clin Oncol. 2008. PMID: 18086801
Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
Pérez-Simón JA, Martino R, Caballero D, Valcarcel D, Rebollo N, de la Cámara R, de Oteiza JP, Heras I, Calvo MV, Sierra J, San Miguel JF; Grupo Español de Trasplante Hematopoyético (GETH). Pérez-Simón JA, et al. Among authors: valcarcel d. Biol Blood Marrow Transplant. 2008 Jun;14(6):664-71. doi: 10.1016/j.bbmt.2008.03.007. Biol Blood Marrow Transplant. 2008. PMID: 18489992 Free article. Clinical Trial.
Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study.
Martínez C, Solano C, Ferrá C, Sampol A, Valcárcel D, Pérez-Simón JA; Spanish Group for Stem Cell Transplantation (Grupo Español de Trasplante Hemopoyético y Terapia Celular). Martínez C, et al. Among authors: valcarcel d. Biol Blood Marrow Transplant. 2009 May;15(5):639-42. doi: 10.1016/j.bbmt.2009.01.014. Epub 2009 Mar 9. Biol Blood Marrow Transplant. 2009. PMID: 19361757 Free article. Clinical Trial.
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Socié G; ATG-Fresenius Trial Group. Finke J, et al. Lancet Oncol. 2009 Sep;10(9):855-64. doi: 10.1016/S1470-2045(09)70225-6. Epub 2009 Aug 18. Lancet Oncol. 2009. PMID: 19695955 Clinical Trial.
174 results